dm+d

87617007

Articles

Safety in Lactation: Alcohol dependence

5 November 2020An assessment of the risks associated with breastfeeding by an alcohol-dependent mother, in terms of sustaining successful breastfeeding and possible exposure of the infant to…

Safety in Lactation: Opioid dependence

27 October 2020An assessment of the risks associated with breastfeeding by an opioid-dependent mother, in terms of sustaining successful breastfeeding and possible exposure of the infant to…

What is the evidence for low dose naltrexone for treatment of multiple sclerosis?

11 February 2020This updated Medicines Q&A evaluates the limited evidence available for low dose naltrexone for treatment of multiple sclerosis.  
Search Articles

Medicine Compliance Aid Stability

NalorexBristol-Myers Squibb Pharmaceuticals Ltd

Bristol-Myers Squibb Pharmaceuticals Ltd
Nalorex
Tablets f/c 50mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Store in airtight containers and protect from light.
3 March 2015

genericAccord Healthcare Ltd

Accord Healthcare Ltd
generic
Tabletsf/c 50mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special storage precautions.
3 March 2015

Lactation Safety Information

For alcohol dependence

For alcohol dependence
Yes
Acamprosate
Very limited published evidence of safety
Only negligible amounts of naltrexone and active metabolite in breast milk
30 July 2020

For opioid dependence

For opioid dependence
Yes
Very limited published evidence of safety
Only negligible amounts of naltrexone and active metabolite in breast milk
30 July 2020